EFFICACY OF LY2951742 IN SUBGROUPS OF PATIENTS WITH MIGRAINE OF DIFFERENT FREQUENCY

被引：0
|
作者：
Skljarevski, V. [1 ]
Martinez, J. [1 ]
Oakes, T. [1 ]
Ferguson, M. [2 ]
Tanaka, Y. [3 ]
Due, M. [4 ]
Schacht, A. [5 ]
机构：
[1] Eli Lilly & Co, Pain Team Med, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Clin Operat, Scarborough, ON, Canada
[3] Eli Lilly & Co, RWA Capabil & Datamart, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Global Sci Commun, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Elanco, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2016年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTC-0111
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [21] Analysis of the relationship between efficacious clinical doses for inhibition of capsaicin-induced dermal blood flow and migraine prevention for the CGRP neutralizing antibody LY2951742
    Collins, E. C.
    Zhang, Q.
    Polzer, J.
    Kielbasa, W.
    Raddad, E.
    Johnson, K. W.
    HEADACHE, 2016, 56 : 8 - 8
  • [22] EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
    P Goadsby
    D Dodick
    E Spierings
    J Scherer
    S Sweeney
    D Grayzel
    The Journal of Headache and Pain, 2014, 15
  • [23] EVALUATION OF TREATMENT-EMERGENT ANTI-DRUG-ANTIBODIES (TE-ADA) FOLLOWING ADMINISTRATION OF LY2951742, A CALCITONIN GENE RELATED PEPTIDE (CGRP) ANTIBODY, TO PATIENTS WITH MIGRAINE
    Miller, B.
    Collins, E.
    Hodsdon, M.
    Camporeale, A.
    Nguyen, H.
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    William, K.
    Yan, Y. Jyun
    CEPHALALGIA, 2016, 36 : 35 - 36
  • [24] Translational Pharmacodynamics of CGRP Monoclonal Antibody LY2951742 in Capsaicin-Induced Dermal Blood Flow Model
    Vermeersch, S.
    Van Hecken, A.
    Abu-Raddad, E.
    Benschop, R.
    Montieth, D.
    Scherer, J.
    Grayzel, D.
    de Hoon, J.
    Collins, E.
    CEPHALALGIA, 2013, 33 (S8) : 249 - 250
  • [25] CHARACTERIZATION OF THE BINDING OF THREE ANTI-CGRP ANTIBODIES EFFECTIVE IN PREVENTING MIGRAINE: A COMPARATIVE CASE STUDY OF ALD403, LY2951742, TEV-48125
    Latham, J.
    Karasek, C.
    Ojala, E.
    Allison, D.
    CEPHALALGIA, 2016, 36 : 144 - 144
  • [26] Peripheral and Central Nervous System Distribution of a CGRP Neutralizing Antibody [125I]-LY2951742 in Male Rats
    Johnson, Michael
    Ellis, Bernice
    Maren, Deanna
    Morin, S. Michelle
    Wroblewski, Victor
    Johnson, Kirk
    NEUROLOGY, 2016, 86
  • [27] Balance Impairments in Different Subgroups of Patients With Migraine
    Carvalho, Gabriela F.
    Bonato, Paolo
    Florencio, Lidiane L.
    Pinheiro, Carina F.
    Dach, Fabiola
    Bigal, Marcelo E.
    Bevilaqua-Grossi, Debora
    HEADACHE, 2017, 57 (03): : 363 - 374
  • [28] Pooled analysis of safety and efficacy of fremanezumab in different racial and ethnic subgroups of patients with migraine
    Charleston, Larry Iv
    Cohen, Joshua
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Lengil, Tamar
    Kim, Byungkun
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 231 - 231
  • [29] Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody
    Goadsby, P. J.
    Dodick, D.
    Martinez, J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V.
    CEPHALALGIA, 2015, 35 : 55 - 55
  • [30] Onset of Efficacy of LY2951742 in Migraine Prevention: Data from a Phase 2a, Randomized, Double-blind, Placebo-controlled Study of a Monoclonal Antibody to Calcitonin Gene-related Peptide (a Post-hoc Analysis)
    Goadsby, P. J.
    Dodick, D. W.
    Martinez, J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V
    HEADACHE, 2015, 55 : 177 - 178
12345